



HAL
open science

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

Daniel Brat, Kenneth Aldape, Howard Colman, Dominique Figarella-branger, Gregory Fuller, Caterina Giannini, Eric Holland, Robert Jenkins, Bette Kleinschmidt-Demasters, Takashi Komori, et al.

► **To cite this version:**

Daniel Brat, Kenneth Aldape, Howard Colman, Dominique Figarella-branger, Gregory Fuller, et al.. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. *Acta Neuropathologica*, 2020, 139 (3), pp.603-608. 10.1007/s00401-020-02127-9. hal-03141576

HAL Id: hal-03141576

<https://hal.science/hal-03141576v1>

Submitted on 22 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Published in final edited form as:

Acta Neuropathol. 2020 March ; 139(3): 603–608. doi:10.1007/s00401-020-02127-9.

cIMPACT-NOW Update 5: Recommended Grading Criteria and Terminologies for IDH-mutant Astrocytomas

Daniel J. Brat¹, Kenneth Aldape², Howard Colman³, Dominique Figarella-Branger⁴, Gregory N. Fuller⁵, Caterina Giannini⁶, Eric C. Holland⁷, Robert B. Jenkins⁶, Bette Kleinschmidt-DeMasters⁸, Takashi Komori⁹, Johan M. Kros¹⁰, David N. Louis¹¹, Catriona McLean¹², Arie Perry¹³, Guido Reifenberger¹⁴, Chitra Sarkar¹⁵, Roger Stupp¹⁶, Martin J. van den Bent¹⁷, Andreas von Deimling¹⁸, Michael Weller¹⁹

¹Department of Pathology, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago IL

²Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD

³Department of Neurosurgery, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

⁴Aix-Marseille Univ, APHM, CNRS, INP, Inst Neurophysiopathol, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France

⁵Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, United States

⁶Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN

⁷Department of Neurosurgery, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA

⁸Department of Pathology, University of Colorado School of Medicine, Aurora, CO

⁹Department of Laboratory Medicine and Pathology, Tokyo Metropolitan Neurological Hospital, Tokyo, Japan

¹⁰Department of Pathology, Erasmus Medical Center, Rotterdam, Netherlands

¹¹Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston MA

¹²Alfred Anatomical Pathology and NNF, Victorian Brain Bank, Carlton, Victoria, Australia

¹³Department of Pathology, University of California San Francisco, San Francisco, CA

¹⁴Department of Neuropathology, Heinrich Heine University, Düsseldorf, and German Cancer Consortium (DKTK), partner site Essen/Düsseldorf, Germany

Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. <https://www.springer.com/aam-terms-v1>

For Correspondence: Daniel J. Brat, MD, PhD, Department of Pathology, Northwestern University Feinberg School of Medicine, Ward Building, 3-140, 303 E. Chicago Ave, Chicago, IL 60611, Phone: 312-503-8144, Daniel.brat@northwestern.edu.

Publisher's Disclaimer: This Author Accepted Manuscript is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication but has not been copyedited or corrected. The official version of record that is published in the journal is kept up to date and so may therefore differ from this version.

¹⁵Department of Pathology, All India Institute of Medical Sciences, New Delhi, India

¹⁶Malnati Brain Tumor Institute, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago IL

¹⁷Department of Neurology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

¹⁸Department of Neuropathology, Institute of Pathology, University of Heidelberg, and Clinical Cooperation Unit Neuropathology, German Cancer Institute (DKFZ), Heidelberg, Germany

¹⁹Department of Neurology, University Hospital and University of Zurich, Zurich Switzerland

Introduction

The diagnostic importance of IDH mutational status in diffuse gliomas was first formally recognized within the updated 4th edition of the WHO Classification of Tumours of the Central Nervous System (2016). Its introduction as a diagnostic marker was based on evidence that incorporation of biomarkers into an integrated diagnosis provided a more reproducible and clinically meaningful classification of diffuse gliomas in adults [20–22]. For IDH-mutant diffuse astrocytic gliomas, the integrated diagnostic entities (and corresponding grades) of the 2016 WHO Classification included: Diffuse Astrocytoma, IDH-mutant (WHO grade II), Anaplastic Astrocytoma, IDH-mutant (WHO grade III) and Glioblastoma, IDH-mutant (WHO grade IV). In contrast to IDH-mutant tumors, IDH-wildtype diffuse astrocytic gliomas are now recognized as distinct clinical and genetic entities that usually have much more aggressive clinical behavior, particularly in adults [5, 13]. While these molecular classifications represented a major step forward, grading schemes for the new diagnostic classes were not modified in parallel. The current grading criteria for diffuse astrocytic gliomas were developed prior to the understanding of molecularly distinct entities, yet the 2016 WHO update applies these same grading criteria for both IDH-mutant and IDH-wildtype gliomas [11, 14].

These legacy grading systems based on morphologic features (mitotic activity, anaplastic nuclear features, microvascular proliferation and necrosis) are not optimal [24, 27]. In particular, multiple retrospective studies have concluded that histologic grading criteria may not stratify risk for patients with IDH-mutant astrocytomas in the WHO grade II and III categories [1, 7, 24, 27, 33]. Yet, other studies have demonstrated that traditional grading schemes are still capable of stratifying risk for these patients [8, 30, 32]. In an attempt to improve risk stratification, several studies have investigated potential morphologic, proliferative or molecular markers that correlate with aggressive clinical behavior and could be incorporated into a more clinically relevant grading scheme [1, 2, 6, 7, 26, 30–32].

We evaluated the literature to determine whether there is sufficient evidence to define molecular genetic or other criteria that could reliably stratify risk among patients with IDH-mutant diffuse astrocytic gliomas or could identify those tumors that would behave most aggressively, with a clinical course corresponding to WHO grade IV. Among the molecular alterations considered were: *CDKN2A/B* homozygous deletion, *CDK4* amplification, *RB1* mutation or homozygous deletion, *PIK3CA* or *PIK3R1* mutations, *PDGFRA* amplification, *MYCN* amplification, global DNA methylation levels, genomic instability and chromosome

14 loss. We also considered whether there were thresholds of proliferative activity, based on mitotic count or Ki-67 indices, or other morphologic features typical of a high grade that might stratify risk better than current criteria. Finally, we considered potential future nosologies for IDH-mutant diffuse astrocytic gliomas in order to more clearly delineate these from IDH-wildtype diffuse gliomas. To achieve these goals, cIMPACT-NOW assembled a group of experienced neuropathologists and clinical neuro-oncologists as Working Committee 1 for Round 2 discussions, which held three teleconferences in an open manner similar to the discussions held at WHO consensus meetings. A subsequent meeting of cIMPACT-NOW in Utrecht, the Netherlands in September 2019 was used to further shape the recommendations and justifications of Working Committee 1.

Molecular Alterations Discussed for Grading of IDH-Mutant Diffuse

Astrocytomas

CDKN2A/B homozygous deletion

Multiple studies have identified homozygous deletion of *CDKN2A/B* as a marker of poor prognosis in patients with IDH-mutant diffuse astrocytic gliomas [1, 2, 8, 16, 26, 30, 32, 33]. Initial observations were that both *CDKN2A/B* homozygous deletions and *CDK4* amplification were enriched among IDH-mutant astrocytomas that were associated with poor prognosis, and that this subset also showed lower levels of global DNA methylation (G-CIMP-low) [6]. Subsequent investigations of *CDKN2A/B* homozygous deletion as an independent marker in WHO grade II and III IDH-mutant astrocytic gliomas confirmed a strong association with shorter survival [7, 8, 26, 33]. A more recent study demonstrated that *CDKN2A/B* homozygous deletion was strongly associated with a poor prognosis in a cohort that included all grades of IDH-mutant astrocytomas (WHO grades II-IV) on univariable analysis [30]. In particular, *CDKN2A/B* homozygous deletions in histologic grade III IDH-mutant astrocytomas were associated with shorter patient survival, similar to WHO grade IV tumors [30]. Other investigations have corroborated these findings [2, 16, 30]. The frequencies of *CDKN2A/B* homozygous deletions reported in IDH-mutant astrocytic gliomas range from 0–12% in WHO grade II, 6–20% in WHO grade III and 16–34% in WHO grade IV tumors [2, 30, 32]. It should be noted that the prognostic associations reported for *CDKN2A/B* homozygous deletion have been based on retrospective cohorts with potentially confounding prognostic parameters, notably age and divergent patterns of care. Moreover, homozygous deletion at 9p21 not only targets the *CDKN2A/B* locus, but also other neighboring genes that have known or suspected tumor suppressive functions [3, 15, 29].

Alteration of other RB pathway genes

CDK4 amplification in IDH-mutant astrocytomas was associated with poor prognosis and its combination with chromosome 14 loss predicted an even shorter overall survival [7, 8]. Other studies have concluded that *CDK4* amplification was not associated with poor prognosis [2, 30]. Homozygous deletion of *RB1* was strongly associated with inferior overall survival among IDH-mutant astrocytomas on univariate analysis, but this finding was not corroborated in other investigations [2, 30]. In a multivariate analysis of two sizable

patient cohorts, Aoki et al. demonstrated that altered RB pathway genes (*CDKN2A/B* homozygous deletion, *CDK4* amplification or *RB1* mutation), when considered together, were a strong and statistically significant predictor of poor prognosis in IDH-mutant astrocytoma patients [1]. When considered by themselves in this study, each of these markers was associated with a less favorable prognosis, although not significantly on univariate analysis. The prognostic role of less common RB pathway gene alterations, such as *CDKN2A/B* point mutation, *CDKN2A/B* promoter methylation or *CDK6* amplification remains unclear and deserves further study.

***PIK3R1* and *PIK3CA* mutations**

On multivariate analysis, *PIK3R1* mutations were an independent marker of poor prognosis in IDH-mutant astrocytomas of WHO grade II or III. *PIK3CA* mutations showed a strong trend towards shorter overall survival but were not an independent marker on multivariable analysis [1].

PDGFRA amplification

Multiple studies have demonstrated that *PDGFRA* amplification is associated with shorter survival among patients with IDH-mutant astrocytic gliomas, including a recent investigation showing its prognostic significance specifically in histologic grade II and III tumors on multivariable analysis [25, 30, 32]. Another study did not uncover this association [1].

MYCN amplification

MYCN amplification was associated with shorter overall survival in patients with IDH-mutant astrocytomas (WHO grades II-IV) on univariable analysis [30].

Genomic instability

Both high levels of copy number variations (CNV) and somatic mutations have been associated with higher histologic grade among IDH-mutant astrocytomas and with shorter overall survival in patients with WHO grade II or III IDH-mutant astrocytomas [1, 9, 28]. In a separate investigation, patients with IDH-mutant astrocytomas that displayed a high CNV level had shorter overall survival than those with low CNV level [30]. There are challenges in the comparison and interpretation of these investigations, since the thresholds for high CNV and somatic mutation varied [23].

Reduced global DNA methylation

In a study of 1,122 diffuse gliomas, a small subset of IDH-mutant diffuse astrocytic gliomas (WHO grades II-IV) were found to have globally reduced levels of DNA methylation (G-CIMP-low) relative to the majority of IDH-mutant astrocytomas, as well as a distinctive gene expression profile [6]. Half of these G-CIMP-low gliomas corresponded to WHO grade IV and the other half were histologically WHO grade II or III. Patients with G-CIMP-low IDH-mutant astrocytomas had shorter overall survival than patients in the G-CIMP-high group. More than 75% of the G-CIMP-low tumors had alterations in RB pathway genes (*CDKN2A/B* homozygous deletion and *CDK4* amplification). Another study, focused

exclusively on IDH-mutant glioblastoma, WHO grade IV, confirmed both the short survival of patients with G-CIMP-low tumors and the association with *CDKN2A/B* homozygous deletion [17].

Other genetic markers

Other genetic markers of interest did not show strong evidence for the ability to stratify risk among patients with IDH-mutant astrocytomas or predict WHO grade IV behavior. Larger or additional studies may provide stronger evidence in the future [6, 8, 12, 24, 30].

Mitotic activity and proliferation indices

The traditional method for stratifying risk among histologic grade II or III diffuse astrocytic gliomas has relied heavily on the identification of mitotic activity. The WHO 2016 indicates that “significant proliferative activity” distinguishes anaplastic astrocytoma, IDH-mutant, WHO grade III from diffuse astrocytoma, IDH mutant, WHO grade II [20]. Based on studies in the pre-WHO 2016 era, astrocytomas with ≥ 2 mitoses in the entire specimen have been shown to be associated with shorter survival than those with 0 or 1 mitoses and this threshold has therefore been used by practicing neuropathologists for the designation of WHO grade III [10, 11, 14]. Specimen size must also be considered. In a very small biopsy, one mitosis may be sufficient, whereas in very large specimens, greater mitotic activity may be necessary [20]. These thresholds for mitotic activity have not been corroborated by several studies of IDH-mutant cohorts [12, 24, 33]. However, others have demonstrated that traditional grading schemes can stratify risk among patients with grade II and III IDH-mutant astrocytomas, but with ample opportunity for improvement [8, 30, 32]. To date, there have been no studies that establish an alternative mitotic count that more reliably stratifies risk among histologic grade II and III IDH-mutant astrocytomas. Similarly, studies of proliferative index (e.g. based on Ki-67) have not identified criteria that unequivocally stratify risk among patients with IDH-mutant astrocytomas [12].

Summary of findings

The currently available evidence from multiple retrospective studies suggests that homozygous deletion of *CDKN2A/B* is associated with shorter survival in patients with IDH-mutant astrocytomas and that its presence corresponds to WHO grade IV clinical behavior. Alterations in other genes encoding members of the RB pathway, including *CDK4* amplification or *RB1* mutation/homozygous deletion, may also be markers of aggressive clinical behavior but the evidence is not as firmly established (e.g., fewer cases or fewer published studies). Several studies have demonstrated *PDGFRA* amplification as a marker of poor prognosis with potential for inclusion as a grading criterion with additional corroborating evidence. While mutations in *PIK3R1* and *PIK3CA*, as well as amplifications in *MYCN*, have been associated with shorter survival, additional cohorts are needed for validation. Genomic instability is a feature corresponding to poor prognosis in patients with IDH-mutant astrocytomas. However, the analyses and thresholds for clinical validation of genomic instability have not been firmly established for application to clinical practice. Similarly, G-CIMP-low DNA methylation pattern has been associated with shorter survival in IDH-mutant astrocytoma, but additional cohorts are needed for validation to more precisely define the G-CIMP-low methylation diagnostic profile as well as to assess

the practicality of testing modalities. There is currently insufficient evidence to establish a new threshold of mitotic activity to discriminate histologic grade II and III IDH-mutant astrocytomas. Overall, with regard to clinical outcomes and grading criteria, we have been cautious in our interpretation of the literature, since most large studies on the relationship between genetic alterations and clinical outcomes have relied on retrospective cohorts in which patients had been treated differently depending on institution, era and histologic classification. Moreover, clinical follow-up times are limited in most studies, which is a particular weakness when assessing prognostic markers in patients whose median overall survival is beyond 10 years.

Proposed Terminology for next WHO classification

The terms used to classify the diffusely infiltrative gliomas are deeply rooted in history and based on presumed tumor cell lineage and levels of differentiation. For the diffuse astrocytic gliomas, we now understand that IDH-wildtype and IDH-mutant tumors represent distinct clinical and genetic entities, despite the similar terms used for their classification by the WHO (diffuse astrocytoma, anaplastic astrocytoma and glioblastoma). Terminologies that more clearly distinguish IDH-mutant and IDH-wildtype diffuse astrocytic gliomas are desirable. One suggestion was to reserve the term “glioblastoma” for those diffuse astrocytic gliomas that are IDH-wildtype and have histologic or genetic features predictive of a highly aggressive clinical behavior corresponding to WHO grade IV [4]. Diffuse astrocytic gliomas that are IDH-mutant would be graded based upon morphologic and genetic features that corresponded to WHO grade II, III or IV clinical behavior. The suggested terminologies, class definitions, and grading criteria for IDH-mutant astrocytomas are summarized in Table 1. We recognize that changes of this type may be viewed as controversial and will require further discussion in context of the next WHO classification, which is scheduled for later 2020 (see Supplemental Text for critiques and responses). Note the use of the Arabic numerals 2, 3 and 4, rather than the Roman numerals II, III and IV, that had traditionally been used for WHO CNS tumor grades; Arabic numerals are suggested in order to harmonize with WHO grading schemes of other tumor types and to reduce the possibility of introducing typographical and interpretive errors (i.e., the distinction of 2 vs 3 is less susceptible to error in a report than *II* vs. *III*).

Grading considerations for IDH-mutant astrocytomas.—IDH-mutant astrocytomas that lack significant mitotic activity, histologic anaplasia, microvascular proliferation, necrosis and *CDKN2A/B* homozygous deletion are referred to as Astrocytoma, IDH-mutant, WHO grade 2. Patients with these tumors have a median overall survival greater than 10 years [2, 30]. An IDH-mutant astrocytoma that contains elevated mitotic activity and histologic anaplasia, yet lacks microvascular proliferation, necrosis and *CDKN2A/B* homozygous deletion, currently fits into the designation of Astrocytoma, IDH-mutant, WHO grade 3. Recognizing that no validated published criteria exist for mitotic count cut-off values for grading IDH-mutant astrocytomas, “significant” mitotic activity remains the criterion to distinguish WHO grade 3 from grade 2 tumors. Most neuropathologists use a threshold of 2 mitoses within the entire specimen, or 1 mitosis in very small biopsies, while large specimen may require more [10, 14, 20]. The extent to which Astrocytoma, IDH-mutant, WHO grade 3 exhibits clinically more aggressive behavior relative to its

WHO grade 2 counterpart remains to be determined. It should be noted that future studies may refine mitotic thresholds for grading and may identify additional genetic alterations associated with more aggressive clinical behavior among WHO grade 2 and 3 IDH-mutant astrocytomas.

IDH-mutant astrocytomas with microvascular proliferation or necrosis or *CDKN2A/B* homozygous deletion, or any combination of these features, correspond to WHO grade 4. These tumors have been formerly considered as “Glioblastoma, IDH-mutant, WHO grade IV”. However, they are clinically and genetically distinct from glioblastoma, IDH-wildtype, and closely related to WHO grade 2 or 3 IDH-mutant astrocytomas. Thus, cIMPACT-NOW recommends that the WHO strongly consider discontinuing the term “Glioblastoma, IDH-mutant, WHO grade IV” and instead recommends referring to these tumors as “Astrocytoma, IDH-mutant, WHO grade 4”. Based on the strength of evidence, cIMPACT-NOW also recommends that *CDKN2A/B* homozygous deletion should be a WHO grade 4 criterion for IDH-mutant astrocytomas. Some studies have concluded that homozygous deletion of *CDKN2A/B* is associated with worse outcome even among patients with histologically defined WHO grade 4 IDH-mutant astrocytomas [16, 30]. Homozygous deletion can be determined by FISH, quantitative PCR, MLPA, microarray- or NGS-based methods. However, immunohistochemistry for p16 does not correlate well with deletion [26].

These recommendations represent the initial steps toward advancing our ability to distinguish clinically relevant subgroups of IDH-mutant astrocytomas at a diagnostic level, and in turn guide patient care and inclusion into clinical trials. In combination with the other cIMPACT-NOW updates, it is further anticipated that such recommendations will contribute to decisions guiding the 5th edition of the WHO brain tumor classification.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This paper has been reviewed by the Steering Committee and Clinical Advisory Panel of cIMPACTNOW [18, 19] and by the International Society of Neuropathology Executive. The authors would like to thank the participants of the cIMPACT-Utrecht meeting, who provided feedback and discussion on the conclusions and recommendations provided in this manuscript: David Capper, Ian Cree, Charles Eberhart, David Ellison, Christine Haberler, Cynthia Hawkins, HK Ng, Brett Orr, Sung-Hye Park, Werner Paulus, Torsten Pietsch, Marc Rosenblum, Brian Rous, Felix Sahm, David Solomon, Uri Tabori, Pieter Wesseling and Valerie White.

References

1. Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura Tet al. (2018) Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. *Neuro Oncol* 20: 66–77 Doi 10.1093/neuonc/nox132 [PubMed: 29016839]
2. Appay R, Dehais C, Maurage C-A, Alentorn A, Carpentier C, Colin Cet al. (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. *Neuro-Onc* 21: 1519–1528 Doi DIO 10.1093/neuonc/noz124

3. Brand F, Forster A, Christians A, Bucher M, Thome CM, Raab MSet al. (2020) FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas. *Acta Neuropathol* 139: 175–192 Doi 10.1007/s00401-019-02067-z [PubMed: 31473790]
4. Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RBet al. (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. *Acta Neuropathol* 136: 805–810 Doi 10.1007/s00401-018-1913-0 [PubMed: 30259105]
5. Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SRet al. (2015) Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *N Engl J Med* 372: 2481–2498 Doi 10.1056/NEJMoa1402121 [PubMed: 26061751]
6. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BAet al. (2016) Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. *Cell* 164: 550–563 Doi 10.1016/j.cell.2015.12.028 [PubMed: 26824661]
7. Cimino PJ, Holland EC (2019) Targeted copy number analysis outperforms histological grading in predicting patient survival for WHO grade II/III IDH-mutant astrocytomas. *Neuro Oncol*: Doi 10.1093/neuonc/noz052
8. Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel Bet al. (2017) Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. *Acta Neuropathol Commun* 5: 39 Doi 10.1186/s40478-017-0443-7 [PubMed: 28532485]
9. Cohen A, Sato M, Aldape K, Mason CC, Alfaro-Munoz K, Heathcock Let al. (2015) DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. *Acta Neuropathol Commun* 3: 34 Doi 10.1186/s40478-015-0213-3 [PubMed: 26091668]
10. Coons SW, Pearl DK (1998) Mitosis identification in diffuse gliomas: implications for tumor grading. *Cancer* 82: 1550–1555 [PubMed: 9554533]
11. Dumas-Duport C, Scheithauer B, O’Fallon J, Kelly P (1988) Grading of astrocytomas. A simple and reproducible method. *Cancer* 62: 2152–2165 Doi 10.1002/1097-0142(19881115)62:10<2152::aid-cnrcr2820621015>3.0.co;2-t [PubMed: 3179928]
12. Duregon E, Bertero L, Pittaro A, Soffietti R, Ruda R, Trevisan Met al. (2016) Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. *Oncotarget* 7: 21190–21198 Doi 10.18632/oncotarget.8498 [PubMed: 27049832]
13. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte Het al. (2015) Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *N Engl J Med* 372: 2499–2508 Doi 10.1056/NEJMoa1407279 [PubMed: 26061753]
14. Giannini C, Scheithauer BW, Burger PC, Christensen MR, Wollan PC, Sebo TJet al. (1999) Cellular proliferation in pilocytic and diffuse astrocytomas. *J Neuropathol Exp Neurol* 58: 46–53 Doi 10.1097/00005072-199901000-00006 [PubMed: 10068313]
15. Hansen LJ, Sun R, Yang R, Singh SX, Chen LH, Pirozzi CJ et al. (2019) MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation. *Cancer Res* 79: 3383–3394 Doi 10.1158/0008-5472.CAN-18-1010 [PubMed: 31040154]
16. Korshunov A, Casalini B, Chavez L, Hielscher T, Sill M, Ryzhova Met al. (2019) Integrated molecular characterization of IDH-mutant glioblastomas. *Neuropathol Appl Neurobiol* 45: 108–118 Doi 10.1111/nan.12523 [PubMed: 30326163]
17. Li KK, Shi ZF, Malta TM, Chan AK, Cheng S, Kwan JSHet al. (2019) Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks. *Neurooncol Adv* 1: vdz015 Doi 10.1093/oaajnl/vdz015 [PubMed: 31667475]
18. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkin Cet al. (2017) Announcing cIMPACT NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. *Acta Neuropathol* 133: 1–3 Doi 10.1007/s00401-016-1646-x [PubMed: 27909809]
19. Louis DN, Aldape K, Brat DJ, Capper D, Ellison DW, Hawkins Cet al. (2017) cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. *Brain Pathol* 27: 851–852 Doi 10.1111/bpa.12457 [PubMed: 27997995]

20. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, World Health Organization, International Agency for Research on Cancer (2016) WHO classification of tumours of the central nervous system. International Agency For Research On Cancer, City
21. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A et al. (2014) International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. *Brain Pathol* 24: 429–435 Doi 10.1111/bpa.12171 [PubMed: 24990071]
22. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK et al. (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. *Acta Neuropathol* 131: 803–820 Doi 10.1007/s00401-016-1545-1 [PubMed: 27157931]
23. Mirchia K, Snuderl M, Galbraith K, Hatanpaa KJ, Walker JM, Richardson TE (2019) Establishing a prognostic threshold for total copy number variation within adult IDH-mutant grade II/III astrocytomas. *Acta Neuropathol Commun* 7: 121 Doi 10.1186/s40478-019-0778-3 [PubMed: 31349875]
24. Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert M et al. (2015) IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. *Acta Neuropathol* 129: 585–596 Doi 10.1007/s00401-015-1398-z [PubMed: 25701198]
25. Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ et al. (2013) PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. *Brain Pathol* 23: 565–573 Doi 10.1111/bpa.12043 [PubMed: 23438035]
26. Reis GF, Pekmezci M, Hansen HM, Rice T, Marshall RE, Molinaro A et al. (2015) CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. *J Neuropathol Exp Neurol* 74: 442–452 Doi 10.1097/NEN.000000000000188 [PubMed: 25853694]
27. Reuss DE, Mamatjan Y, Schrimpf D, Capper D, Hovestadt V, Kratz A et al. (2015) IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. *Acta Neuropathol* 129: 867–873 Doi 10.1007/s00401-015-1438-8 [PubMed: 25962792]
28. Richardson TE, Sathe AA, Kanchwala M, Jia G, Habib AA, Xiao G et al. (2018) Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas. *J Neuropathol Exp Neurol* 77: 542–548 Doi 10.1093/jnen/nly026 [PubMed: 29741737]
29. Roy DM, Walsh LA, Desrichard A, Huse JT, Wu W, Gao J et al. (2016) Integrated Genomics for Pinpointing Survival Loci within Arm-Level Somatic Copy Number Alterations. *Cancer Cell* 29: 737–750 Doi 10.1016/j.ccell.2016.03.025 [PubMed: 27165745]
30. Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F et al. (2018) Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. *Acta Neuropathol* 136: 153–166 Doi 10.1007/s00401-018-1849-4 [PubMed: 29687258]
31. Weller M, Weber RG, Willscher E, Riehemer V, Hentschel B, Kreuz M et al. (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. *Acta Neuropathol* 129: 679–693 Doi 10.1007/s00401-015-1409-0 [PubMed: 25783747]
32. Yang RR, Shi ZF, Zhang ZY, Chan AK, Aibaidula A, Wang W et al. (2019) IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations. *Brain Pathol*: Doi 10.1111/bpa.12801
33. Yoda RA, Marxen T, Longo L, Ene C, Wirsching HG, Keene C et al. (2019) Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma. *J Neuropathol Exp Neurol*: Doi 10.1093/jnen/nlz082

Table 1.

IDH-mutant Astrocytomas

Astrocytoma, IDH-mutant, WHO grade 2

A diffusely infiltrative astrocytic glioma with an *IDH1* or *IDH2* mutation that is well differentiated and lacks histologic features of anaplasia. Mitotic activity is not detected or low^{*}. Microvascular proliferation, necrosis and *CDKN2A/B* homozygous deletions are absent.

Astrocytoma, IDH-mutant, WHO grade 3

A diffusely infiltrative astrocytic glioma with an *IDH1* or *IDH2* mutation that exhibits focal or dispersed anaplasia and displays significant mitotic activity^{*}. Microvascular proliferation, necrosis and *CDKN2A/B* homozygous deletions are absent.

Astrocytoma, IDH-mutant, WHO grade 4

A diffusely infiltrative astrocytic glioma with an *IDH1* or *IDH2* mutation that exhibits microvascular proliferation or necrosis or *CDKN2A/B* homozygous deletion or any combination of these features.

*
= see text regarding mitotic count cut-off values